Comparison of the efficacy of pazopanib and other targeted drugs and suggestions for selection

Pazopanib is a multi-target tyrosine kinase inhibitor that mainly acts on vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and interferon receptors. It is widely used to treat renal cell carcinoma, soft tissue sarcoma and other tumor types. Among many targeted drugs, pazopanib occupies an important position in clinical practice due to its good efficacy and tolerability. However, faced with the selection of multiple targeted drugs, how to compare their efficacy and make a reasonable choice is a key issue in clinical treatment.

Compared with sorafenib (Sorafenib), pazopanib showed similar efficacy in the treatment of advanced renal cell carcinoma, but it was slightly better tolerated and patients were more accepting of the drug. Multiple clinical trials have shown that pazopanib can significantly prolong progression-free survival (PFS), and its side effects are mostly mild to moderate, with common side effects including hypertension, diarrhea and abnormal liver function. In contrast, sorafenib has relatively many adverse reactions, especially hand-foot syndrome and rash, which may affect patients' quality of life.

Compared with anti-angiogenic monoclonal antibodies such as ramucirumab (Ramucirumab) and bevacizumab (Bevacizumab), pazopanib, as a small molecule oral drug, has the advantages of easy use and flexible dosage adjustment. Although antibody drugs are effective, they usually require intravenous infusion and are costly. For some patients, especially those with difficult intravenous access or heavy financial burden, pazopanib is an ideal choice.

In actual clinical practice, the selection of pazopanib should be based on the patient's specific condition, gene mutation status, previous treatment history, and physical tolerance. For example, patients with renal cell carcinoma who have liver dysfunction or a history of cardiovascular disease should use pazopanib with caution and enhanced monitoring. In addition, combination treatment strategies are gradually increasing, and the combined use of pazopanib and immune checkpoint inhibitors is being studied, which is expected to further optimize the treatment effect in the future. Therefore, a reasonable balance between efficacy and safety and individualized medication are the core of the clinical application of pazopanib.

References：https://www.votrient.com/